Explanipedia

Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS Open

Sophie Parker, Melissa Kerr, Barbara C. Walsh, S. Andrea Wijtenburg, Nicholas Prunier , et al. · 2025

AIM: To harmonize two ascertainment and severity rating instruments commonly used for the clinical high risk syndrome for psychosis (CHR-P): the Structured Interview for Psychosis-risk Syndromes (SIPS) and the Comprehensive Assessment of A…

Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program Open

Kang Ik K. Cho, Owen Borders, Yoonho Chung, Michaela Ennis, Grace R. Jacobs , et al. · 2025

Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program Open

Johanna T. W. Wigman, Ann Ee Ching, Yoonho Chung, Habiballah Rahimi-Eichi, Carsten Langholm , et al. · 2025

Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program Open

Nora Penzel, Jean Addington, Celso Arango, Ameneh Asgari-Targhi, Tashrif Billah , et al. · 2025

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample Open

Kelly Allott, Walid Yassin, Luis Alameda, Tashrif Billah, Owen Borders , et al. · 2025

Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program Open

Jean Addington, Lu Liu, Nora Penzel, Ricardo E. Carrión, Vijay A. Mittal , et al. · 2025

This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables a…

Exploring penetrance of clinically relevant variants in over 800,000 humans from the Genome Aggregation Database Open

Sanna Gudmundsson, Moriel Singer‐Berk, Sarah L. Stenton, Michael W. Wilson, Jonah Einson , et al. · 2025

Incomplete penetrance, or absence of disease phenotype in an individual with a disease-associated variant, is a major challenge in variant interpretation. Studying individuals with apparent incomplete penetrance can shed light on underlyin…

Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative Open

Zarina Bilgrami, Eduardo Castro, Carla Agurto, Einat Liebenthal, Michaela Ennis , et al. · 2025

Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative Open

Zarina Bilgrami, Eduardo Castro, Carla Agurto, Einat Liebenthal, Michaela Ennis , et al. · 2025

Speech-based detection of early psychosis is progressing at a rapid pace. Within this evolving field, the Accelerating Medicines Partnership® in Schizophrenia (AMP® SCZ) is uniquely positioned to deepen our understanding of how language an…

Effectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase 3 CONVOKE Randomized Controlled Trial Open

Shaheen E Lakhan, Cornelia Dorner‐Ciossek, Olya Besedina, Faith Dickerson, Claudia Hastedt , et al. · 2025

Background Negative symptoms of schizophrenia, such as lack of motivation, pleasure, social interest, and expression, are key contributors to functional impairments in people with schizophrenia. While psychosocial interventions have demons…

Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial Open

Matin Mortazavi, Zahra Aminifarsani, Inge Winter‐van Rossum, René S. Kahn, W. Wolfgang Fleischhacker , et al. · 2025

LAI antipsychotics significantly delayed treatment discontinuation compared with oral antipsychotics in participants with early phase schizophrenia and comorbid SUD but not in those without SUD. While these findings provide robust evidence…

Shared genetic and environmental influences on altered functional connectivity and schizophrenia liability Open

Karis Colyer‐Patel, Jalmar Teeuw, Rachel Brouwer, Marc M. Bohlken, Marc D. Binder , et al. · 2025

Schizophrenia is characterised by dysconnectivity of several resting-state functional brain networks, potentially reflecting reduced efficiency of brain communication. It remains unclear to what extent dysconnectivity is influenced by gene…

Incidence, Prevalence, and Stability of Remission in Individuals With Clinical High Risk for Psychosis Open

Johanna Seitz‐Holland, Grace Jacobs, Jenna Reinen, Daniel H. Mathalon, Cheryl M. Corcoran , et al. · 2025

Importance While remission from clinical high risk (CHR) for psychosis is a favorable outcome, it is not well characterized over time. Objective To examine remission incidence, prevalence, and stability, and their association with demograp…

Quantitative trait loci mapping of gene expression and chromatin accessibility in primary fibroblast reveals shared allelic effects between Latin American and European ancestries Open

Toni Boltz, Merel Bot, Sandra Lapinska, Tommer Schwarz, Kangcheng Hou , et al. · 2025

Quantitative Trait Locus (QTL) analysis of molecular data has identified genetic variants associated with traits such as gene expression, and colocalization of these functional QTL with GWAS risk loci has offered insights into the genetic …

The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures Open

Daniel H. Mathalon, Spero Nicholas, Brian J. Roach, Tashrif Billah, Suzie Lavoie , et al. · 2025

Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medica…

Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program Open

Johanna T. W. Wigman, Ann Ee Ching, Yoonho Chung, Habiballah Rahimi-Eichi, Erlend Lane , et al. · 2025

Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations Open

Diana O. Perkins, Clark Jeffries, Scott R. Clark, Rachel Upthegrove, Cassandra Wannan , et al. · 2025

Advances in proteomic assay methodologies and genomics have significantly improved our understanding of the blood proteome. Schizophrenia and psychosis risk are linked to polygenic scores for schizophrenia and other mental disorders, as we…

Transdiagnostic Neurocognitive Endophenotypes for Schizophrenia, Bipolar I Disorder and a Broad Psychosis/Bipolar I Disorder Phenotype: A Mega-Analysis of Twin and Sibling Data Open

Eugenia Kravariti, Argyro G. Fragkaki, Anna Georgiades, Alastair G. Cardno, Fergus Kane , et al. · 2025

Background Psychiatric research is increasingly embracing a paradigm shift from categorical diagnoses to neurobiologically meaningful dimensions that cross current diagnostic boundaries. This transposition calls for redefining endophenotyp…

Heterogeneity of morphometric similarity networks in health and schizophrenia Open

Joost Janssen, A. Gallego, Covadonga M. Díaz‐Caneja, Noemi G. Lois, Niels Janssen , et al. · 2025

PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample Open

Stefania Tognin, Sandra Vieira, Dominic Oliver, Alexis E. Cullen, Matthew J. Kempton , et al. · 2025

Bridging Science and Hope: integrating and Communicating Lived experience in Accelerating Medicines Partnership® Schizophrenia Program Open

Ameneh Asgari-Targhi, Beier Yao, Lisa Brown, S. Sánchez García, Arundati Nagendra , et al. · 2025

The Accelerating Medicines Partnership Schizophrenia (AMP® SCZ) program integrates lived experience into psychosis research, leveraging over three decades of foundational studies to improve research quality, promote community engagement, a…

Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program Open

Jean Addington, Lu Liu, Amy Braun, Andrea M. Auther, Monica E. Calkins , et al. · 2025

Clinical ascertainment and clinical outcome are key features of any large multisite study. In the ProNET and PRESCIENT research networks, the Accelerating Medicines Partnership^® Schizophrenia (AMP^®SCZ) Clinical Ascert…

Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program Open

Tashrif Billah, Kang Ik K. Cho, Owen Borders, Yoonho Chung, Michaela Ennis , et al. · 2025

Modern research management, particularly for publicly funded studies, assumes a data governance model in which grantees are considered stewards rather than owners of important data sets. Thus, there is an expectation that collected data ar…

Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program Open

Nora Penzel, Pablo Polosecki, Jean Addington, Celso Arango, Ameneh Asgari-Targhi , et al. · 2025

The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project assesses a large sample of individuals at clinical high-risk for developing psychosis (CHR) and community controls. Subjects are enrolled in 43 sites across 5 contine…

The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program Open

Michael P. Harms, Kang Ik K. Cho, Alan Anticevic, Nicolas R. Bolo, Sylvain Bouix , et al. · 2025

Neuroimaging with MRI has been a frequent component of studies of individuals at clinical high risk (CHR) for developing psychosis, with goals of understanding potential brain regions and systems impacted in the CHR state and identifying p…

Accurate DNA Methylation Predictor for <i>C9orf72</i> Repeat Expansion Alleles in the Pathogenic Range Open

N Ramesh, Alexandria Evans, Kevin Wojta, Zhongan Yang, Marco P. Boks , et al. · 2025

The hexanucleotide (G 4 C 2 ) repeat expansion in the promoter region of C9orf72 is the most frequent genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). In this study, we conducted a genome-wide DNA met…

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample Open

Kelly Allott, Walid Yassin, Luis Alameda, Tashrif Billah, Owen Borders , et al. · 2025

Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairmen…

Neuro- and social-cognition in schizotypal personality disorder and schizophrenia: A spectrum of severity Open

Kim E. Goldstein, Robert H. Pietrzak, Sana Aladin, Sabrina Ng, Chi Chuen Chan , et al. · 2025

Determinants of patient satisfaction in clozapine users: results from the Clozapine International Consortium (CLOZIN) Open

Marte Z. van der Horst, Nini de Boer, Ahmet Müderrisoğlu, Alba Toll, Alde Bouhuis , et al. · 2025

Improving Quality Control Of MRI Images Using Synthetic Motion Data Open

Charles Bricout, Sylvain Bouix, Samira Ebrahimi Kahou, Kang Ik K. Cho, Michael P. Harms , et al. · 2025

MRI quality control (QC) is challenging due to unbalanced and limited datasets, as well as subjective scoring, which hinder the development of reliable automated QC systems. To address these issues, we introduce an approach that pretrains …

René S. Kahn YOU? Author Swipe